Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.63 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.63 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.63 |
| ▸ | EGFR | P00533 | 1/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1162770 | 1.00 | KDM4E (0.63) | KDM4ECISD1SLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL12327330 | 0.88 | MAPT (0.52) | KDM4ECISD1SLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL12327329 | 0.85 | MAPT (0.52) | KDM4ECISD1SLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL305983 | 0.84 | KDM4E (0.72) | KDM4ECISD1SLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL3009380 | 0.84 | KDM4E (0.72) | KDM4ECISD1SLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL305982 | 0.84 | KDM4E (0.72) | KDM4ECISD1SLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL10413058 | 0.84 | EGFR (0.85) | KDM4ECISD1SLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL4600832 | 0.84 | EGFR (0.85) | KDM4ECISD1SLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL4600830 | 0.84 | EGFR (0.85) | KDM4ECISD1SLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL782092 | 0.82 | ALDH1A1 (0.65) | KDM4ECISD1SLC16A3ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2464647-B1 | AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2016-09-21 | — | — | EP | disclosed |
| US-8846673-B2 | Azaindazoles as kinase inhibitors and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2464647-A1 | AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-24 | — | — | US | disclosed |
| WO-2011019780-A1 | AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BTK, ABL1, JAK1 | KDM4E 728/4885CISD1 3010/4885SLC16A3 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.